Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA:603392)
China · Delayed Price · Currency is CNY 41.86
-0.32 (-0.76%)
At close: Feb 6, 2026
SHA:603392 Revenue
Beijing Wantai Biological Pharmacy Enterprise had revenue of 654.81M CNY in the quarter ending September 30, 2025, with 12.50% growth. This brings the company's revenue in the last twelve months to 1.80B, down -27.89% year-over-year. In the year 2024, Beijing Wantai Biological Pharmacy Enterprise had annual revenue of 2.25B, down -59.25%.
Revenue (ttm)
1.80B
Revenue Growth
-27.89%
P/S Ratio
29.48
Revenue / Employee
473.79K
Employees
3,790
Market Cap
52.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | -3.27B | -59.25% |
| Dec 31, 2023 | 5.51B | -5.67B | -50.73% |
| Dec 31, 2022 | 11.19B | 5.43B | 94.51% |
| Dec 31, 2021 | 5.75B | 3.40B | 144.25% |
| Dec 31, 2020 | 2.35B | 1.17B | 98.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharmaron Beijing | 13.54B |
| Chongqing Zhifei Biological Products | 10.91B |
| Shanghai RAAS Blood Products | 7.95B |
| Beijing Tiantan Biological Products | 6.42B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Shanghai Allist Pharmaceuticals | 4.76B |
| Haisco Pharmaceutical Group | 4.27B |
| Hualan Biological Engineering | 4.27B |